Sakar Healthcare Limited (SAKAR.NS)
INR 275.75
(1.54%)
INR 275.75
(1.54%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.54 Billion INR | 15.6% |
| 2022 | 1.33 Billion INR | 4.0% |
| 2021 | 1.28 Billion INR | 35.35% |
| 2020 | 947.39 Million INR | 14.17% |
| 2019 | 829.8 Million INR | 21.58% |
| 2018 | 682.49 Million INR | 28.59% |
| 2017 | 530.76 Million INR | 20.16% |
| 2016 | 441.7 Million INR | 7.14% |
| 2015 | 412.26 Million INR | 17.7% |
| 2014 | 350.27 Million INR | 18.0% |
| 2013 | 296.85 Million INR | 35.51% |
| 2012 | 219.06 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 427.78 Million INR | 3.96% |
| 2024 Q1 | 411.47 Million INR | -4.44% |
| 2023 Q1 | 389.88 Million INR | -4.09% |
| 2023 Q2 | 340.78 Million INR | -12.59% |
| 2023 FY | 1.53 Billion INR | 14.99% |
| 2023 Q4 | 430.58 Million INR | 15.67% |
| 2023 Q3 | 372.25 Million INR | 9.23% |
| 2022 Q2 | 307.08 Million INR | 7.62% |
| 2022 Q4 | 406.51 Million INR | 21.47% |
| 2022 FY | 1.33 Billion INR | 4.0% |
| 2022 Q1 | 285.33 Million INR | -22.01% |
| 2022 Q3 | 334.65 Million INR | 8.98% |
| 2021 Q2 | 316.41 Million INR | 4.57% |
| 2021 Q1 | 302.57 Million INR | 39.56% |
| 2021 FY | 1.28 Billion INR | 35.35% |
| 2021 Q4 | 365.87 Million INR | 23.02% |
| 2021 Q3 | 297.4 Million INR | -6.01% |
| 2020 Q1 | 201.47 Million INR | 10.34% |
| 2020 FY | 947.39 Million INR | 14.17% |
| 2020 Q4 | 216.81 Million INR | -19.08% |
| 2020 Q3 | 267.93 Million INR | 2.59% |
| 2020 Q2 | 261.16 Million INR | 29.63% |
| 2019 Q3 | 222.63 Million INR | -14.6% |
| 2019 Q1 | 163.87 Million INR | -15.65% |
| 2019 FY | 829.8 Million INR | 21.58% |
| 2019 Q2 | 260.68 Million INR | 59.08% |
| 2019 Q4 | 182.6 Million INR | -17.98% |
| 2018 Q3 | 216.68 Million INR | 32.95% |
| 2018 Q4 | 194.28 Million INR | -10.34% |
| 2018 FY | 682.49 Million INR | 28.59% |
| 2018 Q1 | 108.54 Million INR | 0.0% |
| 2018 Q2 | 162.98 Million INR | 50.15% |
| 2017 FY | 530.76 Million INR | 20.16% |
| 2016 FY | 441.7 Million INR | 7.14% |
| 2016 Q4 | 230.01 Million INR | 0.0% |
| 2015 Q2 | 96.79 Million INR | 0.0% |
| 2015 Q3 | 110.25 Million INR | 13.9% |
| 2015 Q4 | 218.66 Million INR | 98.33% |
| 2015 FY | 412.26 Million INR | 17.7% |
| 2015 Q1 | 96.79 Million INR | 17.65% |
| 2014 FY | 350.27 Million INR | 18.0% |
| 2014 Q4 | 82.27 Million INR | 0.0% |
| 2013 FY | 296.85 Million INR | 35.51% |
| 2012 FY | 219.06 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sigachi Industries Limited | 3.98 Billion INR | 61.357% |
| Ind-Swift Limited | 5.02 Billion INR | 69.318% |
| Innova Captab Limited | 10.81 Billion INR | 85.742% |
| Aarti Drugs Limited | 25.28 Billion INR | 93.903% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 91.508% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 67.435% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 99.468% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 87.551% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 88.1% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | 58.033% |
| Morepen Laboratories Limited | 17.01 Billion INR | 90.941% |
| Sequent Scientific Limited | 13.69 Billion INR | 88.745% |
| Wanbury Limited | 5.75 Billion INR | 73.219% |
| Laurus Labs Limited | 50.01 Billion INR | 96.918% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 90.848% |
| Gufic Biosciences Limited | 8.06 Billion INR | 80.888% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 93.248% |
| Alembic Limited | 1.57 Billion INR | 2.107% |
| Hikal Limited | 17.84 Billion INR | 91.361% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 97.478% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 98.695% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 92.772% |
| Themis Medicare Limited | 3.81 Billion INR | 59.617% |
| RPG Life Sciences Limited | 5.82 Billion INR | 73.513% |
| Lupin Limited | 196.56 Billion INR | 99.216% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 63.401% |
| Wockhardt Limited | 27.89 Billion INR | 94.472% |
| Vaishali Pharma Limited | 862.79 Million INR | -78.683% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | 26.13% |
| NATCO Pharma Limited | 40.02 Billion INR | 96.148% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 97.7% |
| FDC Limited | 19.42 Billion INR | 92.065% |
| Divi's Laboratories Limited | 78.45 Billion INR | 98.035% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | 0.133% |
| Eris Lifesciences Limited | 20.09 Billion INR | 92.327% |
| Windlas Biotech Limited | 6.3 Billion INR | 75.566% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.682% |
| Mankind Pharma Limited | 103.34 Billion INR | 98.508% |
| Venus Remedies Limited | 5.91 Billion INR | 73.934% |
| ZIM Laboratories Limited | 3.67 Billion INR | 58.052% |
| Neuland Laboratories Limited | 15.58 Billion INR | 90.108% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 95.528% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 73.445% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 99.19% |
| Bal Pharma Limited | 3.39 Billion INR | 54.552% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.448% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -61.195% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 90.806% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 79.985% |
| Shilpa Medicare Limited | 11.53 Billion INR | 86.63% |
| Orchid Pharma Limited | 8.19 Billion INR | 81.185% |
| Albert David Limited | 3.62 Billion INR | 57.467% |
| Ajanta Pharma Limited | 42.08 Billion INR | 96.337% |
| Hester Biosciences Limited | 3.04 Billion INR | 49.378% |
| Valiant Laboratories Limited | 1.82 Billion INR | 15.319% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 85.336% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 86.609% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | 61.031% |
| Granules India Limited | 45.06 Billion INR | 96.579% |
| Alkem Laboratories Limited | 126.67 Billion INR | 98.783% |
| Medicamen Biotech Limited | 1.79 Billion INR | 14.02% |
| Unichem Laboratories Limited | 16.57 Billion INR | 90.698% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -1.116% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -285.078% |
| Medico Remedies Limited | 1.44 Billion INR | -6.38% |
| Ipca Laboratories Limited | 77.05 Billion INR | 97.999% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 40.532% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 87.964% |
| Brooks Laboratories Limited | 794.86 Million INR | -93.955% |
| Piramal Enterprises Limited | 60.33 Billion INR | 97.445% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 98.546% |
| Suven Life Sciences Limited | 116.92 Million INR | -1218.469% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -205.757% |
| Strides Pharma Science Limited | 40.51 Billion INR | 96.194% |
| Indoco Remedies Limited | 18.17 Billion INR | 91.517% |
| Alpa Laboratories Limited | 1.08 Billion INR | -41.777% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -47.762% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -104.073% |